Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab and Tislelizumab in mCRPC
NCT06866548Phase 1Active, not recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Mar 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teprotumumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Safety and adverse event incidence rate at 6 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
teprotumumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06866548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06866548.